Literature DB >> 3359685

HLA determinants in 70 Danish patients with idiopathic haemochromatosis.

N Milman1, N Graudal, L S Nielsen, K Fenger.   

Abstract

HLA-A, -B, -C and -DR antigens were determined in 70 unrelated Danish patients with idiopathic haemochromatosis. The frequencies of HLA-A and -B antigens compared to 1967 normal control subjects and the relative risk values (RR) were: A3, 80.0% vs. 26.9% (P less than 0.0001), RR = 10.9; B7, 60.0% vs. 26.8% (P less than 0.0001), RR = 4.1; B14, 10.0% vs. 4.5% (P = 0.03), RR = 2.4; B47, 4.3% vs. 0.5% (P less than 0.0001), RR = 9.7; A3, B7, 51.4% vs. 12.2% (P less than 0.0001), RR = 7.6; A3, B14, 10.0% vs. 1.4% (P less than 0.0001), RR = 7.7; A3, B47, 4.3% vs. 0.5% (P less than 0.0001), RR = 9.7. Six patients (8.6%) possessed none of these four typical antigens. There was no association between disease and the frequencies of HLA-C and HLA-DR antigens. The pattern of HLA-antigens associated with haemochromatosis in Denmark shows similarities to those reported both in Germany, being HLA-A3, B7 dominated, and in Brittany, Great Britain and Central Sweden, being HLA-A3, B14 dominated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3359685     DOI: 10.1111/j.1399-0004.1988.tb03450.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  3 in total

1.  Family studies of hereditary hemochromatosis in Denmark and the Faroe Islands.

Authors:  N Milman; N Graudal; L S Nielsen; B Mathiassen; P Tauris; B Lund; J S Kristensen; K Fenger
Journal:  Hum Genet       Date:  1990-07       Impact factor: 4.132

2.  HLA determinants in an Australian population of hemochromatosis patients and their families.

Authors:  K M Summers; K S Tam; J W Halliday; L W Powell
Journal:  Am J Hum Genet       Date:  1989-07       Impact factor: 11.025

3.  HLA-A and -B alleles and haplotypes in hemochromatosis probands with HFE C282Y homozygosity in central Alabama.

Authors:  James C Barton; Ronald T Acton
Journal:  BMC Med Genet       Date:  2002-10-07       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.